MXCT – maxcyte, inc. (US:NASDAQ)

News

MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]
MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com